Orphan Drugs Plus REMS: A Perfect Fit?

Biopharma companies have a decidedly mixed view of FDA's new post-marketing safety authorities. But for one industry segment-companies concentrating in serving very small patient populations suffering from rare diseases-the new regulatory model is decidedly good for business. What does that mean for the future of Big Pharma?